<?xml version="1.0" encoding="UTF-8"?>
<questel-patent-document lang="en" date-produced="20180805" produced-by="Questel" schema-version="3.23" file="US06184008B2.xml">
  <bibliographic-data lang="en">
    <publication-reference publ-desc="Granted patent as second publication">
      <document-id>
        <country>US</country>
        <doc-number>06184008</doc-number>
        <kind>B2</kind>
        <date>20010206</date>
      </document-id>
      <document-id data-format="questel">
        <doc-number>US6184008</doc-number>
      </document-id>
    </publication-reference>
    <original-publication-kind>B2</original-publication-kind>
    <application-reference family-id="12786575" extended-family-id="566919">
      <document-id>
        <country>US</country>
        <doc-number>09336601</doc-number>
        <kind>A</kind>
        <date>19990621</date>
      </document-id>
      <document-id data-format="questel">
        <doc-number>1999US-09336601</doc-number>
      </document-id>
      <document-id data-format="questel_Uid">
        <doc-number>43169056</doc-number>
      </document-id>
    </application-reference>
    <language-of-filing>en</language-of-filing>
    <language-of-publication>en</language-of-publication>
    <priority-claims>
      <priority-claim kind="national" sequence="1">
        <country>US</country>
        <doc-number>33660199</doc-number>
        <kind>A</kind>
        <date>19990621</date>
        <priority-active-indicator>N</priority-active-indicator>
      </priority-claim>
      <priority-claim data-format="questel" sequence="1">
        <doc-number>1999US-09336601</doc-number>
      </priority-claim>
      <priority-claim kind="national" sequence="2">
        <country>JP</country>
        <doc-number>4784097</doc-number>
        <kind>A</kind>
        <date>19970303</date>
        <priority-active-indicator>Y</priority-active-indicator>
      </priority-claim>
      <priority-claim data-format="questel" sequence="2">
        <doc-number>1997JP-0047840</doc-number>
      </priority-claim>
      <priority-claim kind="national" sequence="3">
        <country>US</country>
        <doc-number>3400798</doc-number>
        <kind>A</kind>
        <date>19980303</date>
        <priority-linkage-type>D</priority-linkage-type>
        <priority-active-indicator>N</priority-active-indicator>
      </priority-claim>
      <priority-claim data-format="questel" sequence="3">
        <doc-number>1998US-09034007</doc-number>
      </priority-claim>
    </priority-claims>
    <dates-of-public-availability>
      <publication-of-grant-date>
        <date>20010206</date>
      </publication-of-grant-date>
    </dates-of-public-availability>
    <classifications-ipcr>
      <classification-ipcr sequence="1">
        <text>C12P  13/02        20060101A I20051008RMEP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>P</subclass>
        <main-group>13</main-group>
        <subgroup>02</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051008</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="2">
        <text>C12P  41/00        20060101A I20051008RMEP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>P</subclass>
        <main-group>41</main-group>
        <subgroup>00</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051008</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="3">
        <text>C07C 233/17        20060101A I20051008RMEP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>233</main-group>
        <subgroup>17</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051008</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="4">
        <text>C12N   9/18        20060101A I20051008RMEP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>9</main-group>
        <subgroup>18</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051008</date>
        </action-date>
      </classification-ipcr>
    </classifications-ipcr>
    <classification-national>
      <country>US</country>
      <main-classification>
        <text>435129000</text>
        <class>435</class>
        <subclass>129000</subclass>
      </main-classification>
      <further-classification sequence="1">
        <text>435195000</text>
        <class>435</class>
        <subclass>195000</subclass>
      </further-classification>
      <further-classification sequence="2">
        <text>435197000</text>
        <class>435</class>
        <subclass>197000</subclass>
      </further-classification>
      <further-classification sequence="3">
        <text>435280000</text>
        <class>435</class>
        <subclass>280000</subclass>
      </further-classification>
    </classification-national>
    <classifications-ecla>
      <classification-ecla sequence="1">
        <text>C07C-233/17</text>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>233</main-group>
        <subgroup>17</subgroup>
      </classification-ecla>
      <classification-ecla sequence="2">
        <text>C12N-009/18</text>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>9</main-group>
        <subgroup>18</subgroup>
      </classification-ecla>
      <classification-ecla sequence="3">
        <text>C12P-013/02</text>
        <section>C</section>
        <class>12</class>
        <subclass>P</subclass>
        <main-group>13</main-group>
        <subgroup>02</subgroup>
      </classification-ecla>
      <classification-ecla sequence="4">
        <text>C12P-041/00C2</text>
        <section>C</section>
        <class>12</class>
        <subclass>P</subclass>
        <main-group>041</main-group>
        <subgroup>00C2</subgroup>
      </classification-ecla>
    </classifications-ecla>
    <patent-classifications>
      <patent-classification sequence="1">
        <classification-scheme office="EP" scheme="CPC">
          <date>20130101</date>
        </classification-scheme>
        <classification-symbol>C07C-233/17</classification-symbol>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>233</main-group>
        <subgroup>17</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
        <action-date>
          <date>20151209</date>
        </action-date>
      </patent-classification>
      <patent-classification sequence="2">
        <classification-scheme office="EP" scheme="CPC">
          <date>20130101</date>
        </classification-scheme>
        <classification-symbol>C12N-009/18</classification-symbol>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>9</main-group>
        <subgroup>18</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
        <action-date>
          <date>20151209</date>
        </action-date>
      </patent-classification>
      <patent-classification sequence="3">
        <classification-scheme office="EP" scheme="CPC">
          <date>20130101</date>
        </classification-scheme>
        <classification-symbol>C12P-013/02</classification-symbol>
        <section>C</section>
        <class>12</class>
        <subclass>P</subclass>
        <main-group>13</main-group>
        <subgroup>02</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
        <action-date>
          <date>20151209</date>
        </action-date>
      </patent-classification>
      <patent-classification sequence="4">
        <classification-scheme office="EP" scheme="CPC">
          <date>20130101</date>
        </classification-scheme>
        <classification-symbol>C12P-041/004</classification-symbol>
        <section>C</section>
        <class>12</class>
        <subclass>P</subclass>
        <main-group>41</main-group>
        <subgroup>004</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
        <action-date>
          <date>20151209</date>
        </action-date>
      </patent-classification>
    </patent-classifications>
    <number-of-claims>4</number-of-claims>
    <exemplary-claim>1</exemplary-claim>
    <figures>
      <number-of-drawing-sheets>0</number-of-drawing-sheets>
      <number-of-figures>0</number-of-figures>
      <image-key data-format="questel">US6184008</image-key>
    </figures>
    <invention-title format="original" lang="en" id="title_en">Production of optically active sphingoid compound</invention-title>
    <references-cited>
      <citation srep-phase="applicant">
        <patcit num="1">
          <text>MITSUDA SATOSHI, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4607013</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4607013</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="2">
          <text>NAKANISHI YUJI, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>5290694</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US5290694</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="3">
          <text>IIZUMI TARO, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>5306636</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US5306636</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="4">
          <text>SOLCO BASEL AG</text>
          <document-id>
            <country>EP</country>
            <doc-number>0146810</doc-number>
            <kind>A2</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-146810</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="5">
          <text>KANEGAFUCHI CHEMICAL IND</text>
          <document-id>
            <country>EP</country>
            <doc-number>0189878</doc-number>
            <kind>A2</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-189878</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="6">
          <text>NOVO NORDISK AS</text>
          <document-id>
            <country>EP</country>
            <doc-number>0487541</doc-number>
            <kind>B1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-487541</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="7">
          <text>CHISSO CORP</text>
          <document-id>
            <country>EP</country>
            <doc-number>0657535</doc-number>
            <kind>A2</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-657535</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="8">
          <text>SUNTORY LTD</text>
          <document-id>
            <country>EP</country>
            <doc-number>0472336</doc-number>
            <kind>A1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-472336</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="9">
          <text>AMANO PHARMA CO LTD</text>
          <document-id>
            <country>JP</country>
            <doc-number>H06153965</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>JP06153965</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="10">
          <text>TAKASAGO PERFUMERY CO LTD</text>
          <document-id>
            <country>JP</country>
            <doc-number>H0680617</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>JP06080617</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="11">
          <text>NOVO NORDISK AS</text>
          <document-id>
            <country>WO</country>
            <doc-number>9313200</doc-number>
            <kind>A1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>WO9313200</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="12">
          <text>MITSUBISHI RAYON CO, et al</text>
          <document-id>
            <country>WO</country>
            <doc-number>9534525</doc-number>
            <kind>A1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>WO9534525</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="1">
          <text>Jorgensen et al., Journal of Bacteriology, vol. 173, No. 2, 559-567 (1991).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="2">
          <text>Hirose et al., Tetrahedron, vol. 36, No. 7, 1063-1066 (1995).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="3">
          <text>Sugihara et al., J. Biochem. 112, 598-603 (1992).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="4">
          <text>Sih et al., Tetrahedron, vol. 6, No. 2, 357-360 (1995).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="5">
          <text>Kinoshita et al., Tetrahedron, vol. 52, No. 15, 5397-5406 (1996).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="6">
          <text>Frenken et al., Applied and Environmental Microbiology, vol. 58, No. 12, 3787-3791 (1992).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="7">
          <text>Schrag et al., Structure, vol. 5, No. 2, 187-202 (1997).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="8">
          <text>Julina et al., Helvetica Chimica Acta, vol. 69, pp. 368-373 (1986).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="9">
          <text>Shibuya et al., Tetrahedron Letters, vol. 30, No. 51, pp. 7205-7208 (1989).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="10">
          <text>Nicolaou et al., J. Am. Chem. Soc., vol. 110, pp. 7910-7912 (1988).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="11">
          <text>Abe et al., J. Biol. Chem., vol. 271, No. 24, pp. 14383-14389 (1996).</text>
        </nplcit>
      </citation>
    </references-cited>
    <related-documents>
      <division>
        <relation>
          <parent-doc>
            <document-id>
              <country>US</country>
              <doc-number>3400798</doc-number>
              <kind>A</kind>
              <date>19980303</date>
            </document-id>
            <parent-status>ABANDONED</parent-status>
          </parent-doc>
        </relation>
      </division>
    </related-documents>
    <parties>
      <applicants>
        <applicant data-format="original" app-type="applicant" sequence="1">
          <addressbook lang="en">
            <orgname>Sumitomo Chemical Company Ltd.</orgname>
            <address>
              <address-1>Osaka, JP</address-1>
              <city>Osaka</city>
              <country>JP</country>
            </address>
          </addressbook>
          <nationality>
            <country>JP</country>
          </nationality>
        </applicant>
        <applicant data-format="questel" app-type="applicant" sequence="2">
          <addressbook lang="en">
            <orgname>SUMITOMO CHEMICAL</orgname>
          </addressbook>
          <nationality>
            <country>JP</country>
          </nationality>
        </applicant>
      </applicants>
      <inventors>
        <inventor data-format="original" sequence="1">
          <addressbook lang="en">
            <name>Ohta, Hiromichi</name>
            <address>
              <address-1>Tokyo, JP</address-1>
              <city>Tokyo</city>
              <country>JP</country>
            </address>
          </addressbook>
          <nationality>
            <country>JP</country>
          </nationality>
        </inventor>
        <inventor data-format="original" sequence="2">
          <addressbook lang="en">
            <name>Sugai, Takeshi</name>
            <address>
              <address-1>Yokohama, JP</address-1>
              <city>Yokohama</city>
              <country>JP</country>
            </address>
          </addressbook>
          <nationality>
            <country>JP</country>
          </nationality>
        </inventor>
        <inventor data-format="original" sequence="3">
          <addressbook lang="en">
            <name>Ishii, Takeshi</name>
            <address>
              <address-1>Takarazuka, JP</address-1>
              <city>Takarazuka</city>
              <country>JP</country>
            </address>
          </addressbook>
          <nationality>
            <country>JP</country>
          </nationality>
        </inventor>
        <inventor data-format="original" sequence="4">
          <addressbook lang="en">
            <name>Mitsuda, Satoshi</name>
            <address>
              <address-1>Takarazuka, JP</address-1>
              <city>Takarazuka</city>
              <country>JP</country>
            </address>
          </addressbook>
          <nationality>
            <country>JP</country>
          </nationality>
        </inventor>
      </inventors>
      <agents>
        <agent sequence="1" rep-type="agent">
          <addressbook lang="en">
            <orgname>Birch, Stewart, Kolasch &amp; Birch, LLP</orgname>
          </addressbook>
        </agent>
      </agents>
    </parties>
    <examiners>
      <primary-examiner>
        <name>Lilling, Herbert J.</name>
      </primary-examiner>
    </examiners>
    <lgst-data>
      <lgst-status>LAPSED</lgst-status>
    </lgst-data>
  </bibliographic-data>
  <abstract format="original" lang="en" id="abstr_en">
    <p id="P-EN-00001" num="00001">
      <br/>
      An industrially advantageous production method of an optically active alcohol useful for cosmetics and medical supplies or production intermediates thereof using an esterase having an ability to selectively hydrolyze an optically active sphingoid compound.
    </p>
  </abstract>
  <description format="original" lang="en" id="desc_en">
    <p num="1">This application is a divisional of application No. 09/034,007, filed on Mar. 3, 1998, now abandoned the entire contents of which are hereby incorporated by reference.</p>
    <heading>BACKGROUND OF THE INVENTION</heading>
    <p num="2">
      1.
      <br/>
      Field of the Invention
    </p>
    <p num="3">The present invention relates to a method for producing an optically active sphingoid compound.</p>
    <p num="4">2. Description of the Related Art</p>
    <p num="5">Optically active sphingoid compounds having optically active erythro amino alcohol moiety have been used in cosmetics and medical supplies for treatment of hair and skin or production intermediates thereof.</p>
    <p num="6">
      Conventionally, these compounds are extracted and separated mainly from epidermis tissue of animals such as cows and pigs, alternatively obtained by several synthetic steps.
      <br/>
      However, they are expensive and a stable supply thereof is difficult since the production amount is limited.
      <br/>
      Therefore, a further provision of a convenient method for producing the said compound has been desired.
    </p>
    <heading>SUMMARY OF THE INVENTION</heading>
    <p num="7">An object of the present invention is to provide: a method for producing an optically active erythro sphingoid ester of the formula I:  (Chemical Structure image '1' not included in text)</p>
    <p num="8">wherein R1 and R2 may be the same or different and represent an aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, and</p>
    <p num="9">
      R3 and R4 may be the same or different and represent an acyl group having 1 to 7 carbon atoms,
      <br/>
      which comprises:
      <br/>
      allowing a racemic mixture comprising the optically active erythro sphingoid ester of the formula I as defined above and its enantiomer to contact with an esterase having the ability to selectively hydrolyze the said enantiomer of the optically active erythro sphingoid ester of the formula I to produce an optically active erythro sphingoid alcohol compound of the formula II:  (Chemical Structure image '2' not included in text)
    </p>
    <p num="10">
      wherein R1 and R2 have the same meaning as defined above, and
      <br/>
      R3 *, and R4 * represent a hydrogen atom and an acyl group having 1 to 7 carbon atoms provided that R3 * and R4 * do not simultaneously represent an acyl group having 1 to 7 carbon atoms; and
      <br/>
      recovering the optically active erythro sphingoid ester of the formula I.
    </p>
    <heading>DESCRIPTION OF THE PREFERRED EMBODIMENT</heading>
    <p num="11">Next, a description will be made to the racemic mixture comprising the optically active erythro sphingoid ester compound of the formula I as defined above and its enantiomer represented by the formula II as defined above.</p>
    <p num="12">
      Examples of the aliphatic hydrocarbon having 7 to 31 carbon atoms which may he substituted by one or more hydroxyl groups, represented by R1 and R2, for example, include:
      <br/>
      a liner or branched alkyl group having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups,
      <br/>
      a liner or branched alkenyl group having 7 to 31 carbon atoms which has one or more double bonds and may be substituted by one or more hydroxyl groups, and the like.
    </p>
    <p num="13">A liner or branched alkyl group having 7 to 31 carbon atoms which may be substituted by one to three hydroxyl groups, a liner or branched alkenyl group having 7 to 31 carbon atoms which has one to three double bonds and may be substituted by one to three hydroxyl groups and the like, are preferred.</p>
    <p num="14">Among the aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, for R1 and R2, the aliphatic hydrocarbon having 7 to 26 carbon atoms which may be substitiuted by one or more hydroxyl groups are preferred.</p>
    <p num="15">Specific examples of the above-described preferred alkyl or alkenyl groups include:</p>
    <p num="16">a heptyl group, tridecyl group, tetradecyl group, pentadecenyl group, hexadecyl group, heptadecyl group, octadecyl group, nonadecyl group, eicosyl group, heneicosyl group, docosyl group, tricosyl group, tetracosyl group, pentacosyl group, hexacosyl group, heptacosyl group, octacosyl group, nonacosyl group, tracontyl group, hentriacontyl group, 1-tridecenyl group, 1-tetradecenyl group, 1-pentadecenyl group, 1-hexadecenyl group, 1-heptadecenyl group, 1-octadecenyl group, 1-nonadecenyl group, 1-eicosenyl group, 1-hydroxytetradecyl group, 1-hydroxypentadecyl group, 1-hydroxthexadecyl group, 1-hydroxtheptadecyl group, 1-hydroxyoctadecyl group, 1-hydroxynondecyl group, 1-hydroxyeicosyl group, 1-hydroxtheneicosyl group, 1-hydroxydocosyl groun, 1-hydroxytricosyl group, 1-hydroxytetracosyl group, 1-hydroxypentacosyl group, 1-hydroxyhexacosyl group, 1-hydroxyheptacosyl group, 12-methyl-tridecyl group, 14-methy-1-pentadecenyl group, 14-methyl-heptadecyl group and the like</p>
    <p num="17">Examples of the acyl group having 1 to 7 carbon atoms for R3 and R4 include an alkylcarbonyl group having 2 to 7 carbon atoms and the like.</p>
    <p num="18">Specific examples of the acyl group include an acetyl group, propionyl group, butyryl group and the like.</p>
    <p num="19">An acetyl group is more preferred.</p>
    <p num="20">Specific examples of the racemic erythro sphingoid ester include:</p>
    <p num="21">
      N-heptadecanoyl-1,3-O,O-diacetyl-2-amino-4-hexadecene-1,3-diol,
      <br/>
      N-heptadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-heptadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-heptadecanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol,
      <br/>
      N-heptadecanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol,
      <br/>
      N-heptadecanoyl-1,3-O,O-dibutyryl-2-aminoeicosane-1,3-diol,
      <br/>
      N-heptadecanoyl-1,3-O,O-diacetyl-2-aminoheptacosane-1,3-diol,
      <br/>
      N-octadecanoyl-1,3-O,O-diacetyl-2-amino-15-methylhexadecane-1,3-diol,
      <br/>
      N-octadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-octadecanoyl-1,3-O,O-dibutyryl-2-aminohexadecane-1,3-diol,
      <br/>
      N-octadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecence-1,3-diol,
      <br/>
      N-octadecanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol,
      <br/>
      N-octadecanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol,
      <br/>
      N-octadecanoyl-1,3-O,O-dibutyryl-2-aminoheptacosane-1,3-diol,
      <br/>
      N-2'-hydroxyoctadecanoyl-1,3-O,O-diacetyl-2-amino-15-methylhexadecane-1,3-diol,
      <br/>
      N-2'-hydroxyhexadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-2'-hydroxyhexadecanoyl-1,3-O,O-dibutyryl-2-aminohexadecane-1,3-diol,
      <br/>
      N-2'-hydroxyeicosanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-2'-hydroxyeicosanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol,
      <br/>
      N-2'-hydroxytetracosanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol,
      <br/>
      N-2'-hydroxyhexacosanoyl-1,3-O,O-dibutyryl-2-aminoheptacosane-1,3-diol,
      <br/>
      N-docosanoyl-1,3-O,O-dibutyryl-2-amino-15-methyhexadecane-1,3-diol,
      <br/>
      N-tetracosanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-hexacosanoyl-1,3-O,O-dibutyryl-2-aminohexadecane-1,3-diol,
      <br/>
      N-methyloctadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-pentacosanoyl-1,3-O,O-diacetyl-2-amino-4-docosene-1,3-diol,
      <br/>
      N-pentacosanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-pentacosanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol, and the like.
      <br/>
      These sphingoid esters can be obtained, for example, by a method disclosed by T. Kolter et al. (Tetrahedron, 50, p.13425(1994)).
    </p>
    <p num="22">The esterase includes an esterase, protease and the like in addition to a narrowly-defined lipase, and may be derived from animals such as hogs, human and the like, derived from plants such as ricinus and the like, or derived from microorganisms belonging to Aspergillus, Candida, Fusarium, Geotrichum, Mucor, Nocardia, Penicillium, Rhizopus, Saccharomyces, Acromobacter, Acinetobacter, Alcaligenes, Chromobacterium, Escherichia, Pseudomonas, Sphingomonas, Bacillus, Burkholderia, Moraxella, Lactobacillus, Staphylococcus, Serratia, Yarrowia and the like.</p>
    <p num="23">An esterase produced by a transformed host organism, into which an isolated gene of the esterase is introduced by using recombinant DNA technology, can be used in the present invention</p>
    <p num="24">As the host organism, an organism belonging to the same genus or a host organism belonging to the different genus can be used.</p>
    <p num="25">As a more specific example of the esterase, a protein having an amino acid sequence represented by SEQUENCE ID NO: 2 or a sequence in which one or more amino acids in the amino acid sequence are added, deleted or substituted, is listed.</p>
    <p num="26">SEQ ID NO:1 represents the DNA sequence coding for the amino acid sequence represented by SEQ ID No:2.</p>
    <p num="27">A microorganism (E. coli JM 109/pAL 612 strain) producing the protein having the amino acid sequence represented by SEQUENCE ID NO: 2 has been deposited as FERM-BP5740 (accepted date: Nov. 7, 1996) under the Budapest Treaty at the Ministry of International Trade and Industry, Agency of Industrial Science and Technology, National Institute of Biochemical and Human-Technology.</p>
    <p num="28">The esterase may be used in the form of a microorganism containing the same or a cell culture, however, it may also be separated from the culture or tissue containing the esterase and utilized in the form of a crude enzyme, purified enzyme and the like, if necessary.</p>
    <p num="29">
      These crude enzyme, purified enzyme and the like can be prepared by a conventional method such as, for example,
      <br/>
      (1) ultrasonic treatment,
      <br/>
      (2) grinding treatment using glass beads or alumina,
      <br/>
      (3) French press treatment,
      <br/>
      (4) treatment with an enzyme such as lysozyme and the like,
      <br/>
      (5) bacteria, cell, tissue or the like is ground by Warinq blender treatment and the like,
      <br/>
      (6) the resulted ground material is salted out using ammonium sulfate and the like,
      <br/>
      (7) precipitation by an organic solvent or an organic polymer such as polyethylene glycol and the like,
      <br/>
      (8) various chromatographies such as ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, affinity chromatography and the like, and
      <br/>
      (9) electrophoresis and the like.
    </p>
    <p num="30">The esterase may be insolubilized by a immobilization such as a carrier binding method in which the esterase is bound to a carrier by a covalent bond, ion bond, adsorption and the like, an entrapment method ir which the esterase is confined in gel structure.</p>
    <p num="31">The reaction is usually carried out from about 20 (degree)  C. to about 70 (degree)  C., preferably from about 25 (degree)  C. to about 40 (degree)  C. The reaction is preferably conducted in a two-layer system comprising an organic solvent which dissolves the sphingoid ester compound of the formula I as defined above and its enantiomer and a buffer solution which dissolves tile above-described esterase.</p>
    <p num="32">Examples of the organic solvent include, for example, decane and the like.</p>
    <p num="33">Examples of the buffer solution include a usual buffer solution having pH of about 5 to about 8.</p>
    <p num="34">The reaction time can be optionally set, for example, from about 1 hour to about 1 week.</p>
    <p num="35">For recovery of the optically active erythro sphingoid ester of the formula I from the reaction solution, conventional methods such as, for example, solvent extraction, fractional distillation, column chromatography and the like may be used, and optionally, these methods may also be appropriately combined for use, if necessary.</p>
    <p num="36">The optically active erythro sphingoid ester of the formula I as defined above can be allowed to react with either an acid or a base to effect a hydrolysis reaction by a conventional method to obtain an optically active erythro sphingoid alcohol of the formula I':  (Chemical Structure image '3' not included in text)</p>
    <p num="37">wherein R1 and R2 are the same as defined for the formula I above.</p>
    <p num="38">
      Examples of thus obtained optically active erythro sphingoid alcohols includes optically active erythro isomers of the following compounds such as:
      <br/>
      N-heptadecanoyl-2-amino-4-hexadecene-1,3-diol,
      <br/>
      N-heptadecanoyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-heptadecanoyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-heptadecanoyl-2-aminooctadecane-1,3,4-triol,
      <br/>
      N-heptadecanoyl-2-aminoeicosane-1,3-diol,
      <br/>
      N-heptadecanoyl-2-aminoeicosane-1,3-diol,
      <br/>
      N-heptadecanoyl-2-aminoheptacosane-1,3-diol,
      <br/>
      N-octadecanoyl-2-amino-15-methylhexadecane-1,3-diol,
      <br/>
      N-octadecanoyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-octadecanoyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-octadecanoyl-2-aminooctadecane-1,3,4-triol,
      <br/>
      N-octadecanoyl-2-aminoeicosane-1,3-diol,
      <br/>
      N-octadecanoyl-2-aminoheptacosane-1,3-diol,
      <br/>
      N-2'-hydroxyoctadecanoyl-2-amino-15-methylhexadecane-1,3-diol,
      <br/>
      N-2'-hydroxyhexadecanoyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-2'-hydroxyeicosanoyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-2'-hydroxyeicosanoyl-2-aminooctadecane-1,3,4-triol,
      <br/>
      N-2'-hydroxytetracosanoyl-2-aminoeicosane-1,3-diol,
      <br/>
      N-2'-hydroxyhexaconoyl-2-aminoheptacosane-1,3-diol,
      <br/>
      N-docosanoyl-2-amino-15-methyhexadecane-1,3-diol,
      <br/>
      N-tetracosanoyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-hexacosanoyl-2-aminohexadecane-1,3-diol,
      <br/>
      N-methyloctadecanoyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-pentacosanoyl-2-amino-4-docosene-1,3-diol,
      <br/>
      N-pentacosanoyl-2-amino-4-octadecene-1,3-diol,
      <br/>
      N-pentacosanoyl-2-aminoeicosane-1,3-diol, and the like.
    </p>
    <heading>EXAMPLE</heading>
    <p num="39">The following examples further illustrate the present invention in detail, but they are not to be construed to limit the scope thereof.</p>
    <p num="40">Example 1</p>
    <p num="41">To a mixed solution of 10 ml decane and 100 ml of a phosphate buffer solution were added 1.03 g of racemic erythro-3-acetoxy-2-stearoylaminohexadecyl acetate and 50 mg of an esterase prepared in Reference Example 1 below, and the resulted mixture was reacted by stirring at 30 (degree)  C. The reaction was traced by TLC �silica gel, hexane:ethyl acetate (2:1), chloroform:methanol (15:1)�.</p>
    <p num="42">
      The reaction was continued for 2 days, and then, the reaction solution was diluted with ethyl acetate, and then extracted with chloroform.
      <br/>
      The recovered organic solvent layer was washed with salt water, then, dried over anhydrous sodium sulfate, and the filtered solution was concentrated under reduced pressure to obtain a residue.
      <br/>
      The resulted residue was separated by silica gel column chromatography using hexane:ethyl acetate (5:1) and chloroform:methanol (30:1) as eluent.
      <br/>
      A sample of the eluted (+)-(2S,3R)erythro-3-acetoxy-2-stearoylaminohexadecyl acetate (264.9 mg) was hydrolyzed, then converted to (4R,5S)-erythro-2,2-dimethyl-5-stearoylamino-4-tridecyl-1,3-dioxane in the presence of p-toluenesulfonic acid, 2,2-dimethoxypropane and acetone, and the optical purity was analyzed by 1 H-NMR to find it was &gt;95%e.e.
    </p>
    <p num="43">Then, a sample of the elated (-)-(2R,3S)-3-acetoxy-2-stearoylaminohexadecane-1-ol (481.8 mg) was hydrolyzed, and compared with angle of rotation of (-)-(2R,3S)-erythro-2-stearoylamino-1,3-hexadecanediol, to find a optical purity of 16%e.e</p>
    <p num="44">
      Then, a part of the eluted (-)-(2R,3S)-erythro-2-stearoylamino-1,3-hexanediol (214.8 mg) was converted to (4S,5R)-erythro-2,2-dimethyl-5-stearoylamino-4-tridecyl-1,3-dioxane according to the method as described above.
      <br/>
      The optical purity was analyzed by 1 H-NMR to find it was &gt;95%e.e.
    </p>
    <p num="45">Example 2</p>
    <p num="46">To a mixed solution of 10 ml decane and 100 ml of a phosphate buffer solution were added 10.2 mg of racemic erythro-3-acetoxy-2-stearoylaminohexadecyl acetate and 10.8 mg of an immobolized esterase prepared in Reference Example 2 below, and the resulted mixture reacted under stirring at 30 (degree)  C. The reaction was traced by TLC �silica gel, hexane:ethyl acetate (2:1), chloroform:methanol (15:1)�.</p>
    <p num="47">The reaction was continued for 2 days, and then, the product (+)-(2S,3R)-erythro-3-acetoxy-2-stearoylaminohexadecyl acetate was separated according to the method described in Example 1.</p>
    <p num="48">Then a sample of the-separated product was hydrolyzed, then reacted with  ALPHA -methoxy- ALPHA -trifluoromethylphenyl acetate (hereinafter, referred to as MTPA), converted to a bis-MTPA ester, then, optical purity was analyzed by 1 H-NMR.</p>
    <p num="49">(+)-(2S, 3R) -erythro-2-acetoxy-2-stearoylaminohexadecyl acetate was obtained in a yield of 50%, and the optical purity was &gt;95%e.e.</p>
    <p num="50">Reference Example 1</p>
    <p num="51">Preparation of Esterase</p>
    <p num="52">
      Recombinant E. coli JM109/pAL612 strain (FREM-BP 5740) was incubated in 100 ml of a LB medium (manufactured by Difco) containing 50 mg/L of ampicillin and 1 mM of isopropyl thio- BETA -D-galactoside, at 37 (degree)  C. for 16 hours, then the culture was subjected to centrifuged (6000 rpm, 10 minutes) to recover microorganism The recovered microorganism was suspended i n a 10 ml of 100 mM phosphate buffer solution (pH 7.0), then was broken by ultrasonic wave, and the broken material was centrifuged to obtain a crude enzyme extract solution.
      <br/>
      Then, the resulted crude enzyme extract solution was freeze-dried to obtain a crude enzyme powder.
    </p>
    <p num="53">Reference Example 2</p>
    <p num="54">Immobilization of Esterase</p>
    <p num="55">
      To a 10 ml of 0.1 M phosphate buffer solution (pH 7.0) into which Triton X-100 (TRM of Union Carbide Chemicals and Plastics) (300 mg) was dissolved was added 1 g of the enzyme powder obtained in Reference Example 1, then, Florysil (TRM of U.S. Silica Company, purchased from Aldrich Japan) (8.7 mg) was added in ice water.
      <br/>
      The resulted mixture was frozen at -78 (degree)  C. then freeze-dried to obtain 1.4 g of an immobilized powdery enzyme.
    </p>
  </description>
  <claims format="original" lang="en" id="claim_en">
    <claim num="1">
      <claim-text>What is claimed is:</claim-text>
      <claim-text>1.</claim-text>
      <claim-text>A method for producing an optically active erythro sphingoid ester of the formula I:  (Chemical Structure image '4' not included in text)</claim-text>
      <claim-text>wherein R1 and R2, may be the same or different, represent an aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, and</claim-text>
      <claim-text>R3 and R4 may be the same or different and represent an acyl group having 1 to 7 carbon atoms, which comprises: allowing a racemic mixture comprising the optically active sphingoid ester of the formula I as defined above and its enantiomer to contact with an esterase having an ability to selectively hydrolyze the said enatiomer of the optically active sphingoid ester of the formula I to produce an optically active sphingoid alcohol compound of the formula II:  (Chemical Structure image '5' not included in text)</claim-text>
      <claim-text>wherein R1 and R2 have the same meaning as defined above, and R3 *, and R4 * represent a hydrogen atom and an acyl group having to 7 carbon atoms provide that R3 *, and R4 * do not simultaneously represent an acyl group having 1 to 6 carbon atoms;</claim-text>
      <claim-text>and recovering the optically active erythro sphingoid ester of the formula I.</claim-text>
    </claim>
    <claim num="2">
      <claim-text>2. A method for producing an optically active erythro sphingoid alcohol of the formula I':  (Chemical Structure image '6' not included in text)</claim-text>
      <claim-text>wherein R1 and R2 are the same as defined in claim 1, which comprises: allowing the recovered optically active erythro sphingoid ester of the formula I as defined in claim 1 to hydrolysis reaction.</claim-text>
    </claim>
    <claim num="3">
      <claim-text>3. The method according to claim 1, wherein the esterase is a protein having an amino acid sequence of SEQUENCE ID NO: 2.</claim-text>
    </claim>
    <claim num="4">
      <claim-text>4. The method according to claim 2, wherein the esterase is a protein having an amino acid sequence of SEQUENCE ID NO: 2.</claim-text>
    </claim>
  </claims>
</questel-patent-document>